Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating income | -$13.8M | -$58.6M | -$150M | -$171M | -$242M | -$344M | -$468M |
| Net income | -$14.9M | -$59.4M | -$149M | -$168M | -$236M | -$317M | -$446M |
| EPS (diluted) | -$6.08 | -$4.13 | -$2.93 | -$3.23 | -$3.95 | -$3.37 | -$3.47 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.8M | -$46.5M | -$120M | -$154M | -$188M | -$292M | -$403M |
| Capital expenditures | $1.65M | $1.16M | $3.62M | $3.07M | $729K | $2.38M | $1.92M |
| Free cash flow | -$13.5M | -$47.7M | -$123M | -$157M | -$189M | -$295M | -$405M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14.6M | $301M | $201M | $172M | $122M | $435M | $893M |
| Total assets | $16.4M | $353M | $426M | $306M | $165M | $691M | $1.19B |
| Total liabilities | $2.40M | $11.0M | $57.5M | $54.0M | $73.8M | $61.4M | $215M |
| Long-term debt | — | — | — | — | — | $0.00 | $149M |
| Shareholders' equity | $14.0M | $342M | $368M | $252M | $91.3M | $630M | $972M |
| Retained earnings | -$19.7M | -$79.2M | -$228M | -$397M | -$633M | -$950M | -$1.40B |
| Shares (wtd avg diluted) | 2.59M | 45.1M | 51.6M | 55.6M | 61.5M | 102M | 165M |
Every figure is extracted from Dyne Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.